Fremanezumab consistently improves migraine days across diverse real-world and RCT populations
Background
Migraine is a highly disabling neurological disorder characterized by severe headaches, significantly impacting quality of life. Conventional preventive therapies for migraine often have suboptimal efficacy or are limited by side effects, leaving many patients undertreated. The emergence of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) like fremanezumab has offered a new therapeutic avenue by targeting the CGRP pathway, a key mediator in migraine pathophysiology. This review assesses the combined evidence from randomized controlled trials (RCTs) and real-world evidence (RWE) studies to provide a comprehensive understanding of fremanezumab's effectiveness.
Study Design
Researchers conducted a narrative review to evaluate the complementary value of RCTs and RWE studies for fremanezumab. They systematically searched Embase, MEDLINE, MEDLINE In-Process, Cochrane databases, bibliographies, and conference materials for published data on fremanezumab efficacy and effectiveness. Electronic database searches were limited to articles published between January 2017 and September 2023, while conference abstract searches covered January 2022 to September 2023. The review identified 48 publications for inclusion, comprising 14 RCTs (from 10 unique trials) and 34 RWE studies (from 23 unique studies).
Results
Across 14 RCTs and 34 RWE studies, fremanezumab consistently demonstrated improvements in monthly migraine and headache days. RCTs, typically 8-12 weeks long (with open-label extensions up to 52 weeks), often excluded individuals receiving preventive migraine treatment at baseline, those with previous preventive treatment failures, prior exposure to CGRP pathway mAbs, or severe comorbidities. In contrast, most RWE studies included a broader patient population, with durations of ≥3 months and some following participants for up to 2 years. These RWE studies encompassed patients with characteristics often excluded from RCTs, such as those with major depressive disorder (e.g., the UNITE study) or those with ≥2 prior preventive therapy failures (e.g., the FOCUS studies).
Key Findings
- Fremanezumab consistently improved monthly migraine and headache days.
- Benefits were observed from as early as 4 weeks and sustained for up to 52 weeks.
- Real-world evidence confirmed fremanezumab's efficacy in broader, more diverse patient populations than RCTs.
- RCTs typically lasted 8-12 weeks, while RWE studies often extended ≥3 months (up to 2 years).
- The review included 48 publications (14 RCTs, 34 RWE studies) on fremanezumab.
Why It Matters
The combined evidence from RCTs and RWE studies provides a robust picture of fremanezumab's effectiveness, confirming its utility beyond highly controlled trial settings. This review highlights that fremanezumab is effective in a broader, more diverse patient population, including those with comorbidities or a history of multiple treatment failures. For clinicians and patients, this means greater confidence in prescribing fremanezumab for individuals who might not fit strict RCT criteria, potentially expanding access to effective preventive migraine treatment. The sustained benefits observed for up to 52 weeks also support long-term use, offering a more durable solution for chronic migraine management.
fremanezumab
migraine
cgrp-inhibitor
real-world-evidence
rct
review